12:00 AM
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bavituximab: Phase I started

Peregrine said researchers at the University of Texas Southwestern Medical Center (Dallas, Texas) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 825 mg/m 2 once-weekly bavituximab for...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >